Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
grade F 44.72 -3.08% -1.42
RGNX closed down 3.08 percent on Friday, May 17, 2019, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RGNX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -3.08%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.08%
NR7 Range Contraction -3.08%
Up 3 Days in a Row Strength -3.08%
Oversold Stochastic Weakness -3.08%
Lower Bollinger Band Walk Weakness -2.12%
Oversold Stochastic Weakness -2.12%
Slingshot Bearish Bearish Swing Setup -0.18%

Older signals for RGNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Medical Genetics Wet Age Related Macular Degeneration Applied Genetics Retinitis Pigmentosa Gene Delivery Adeno Associated Virus X Linked Retinitis Pigmentosa Homozygous Familial Hypercholesterolemia Iduronidase
Is RGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 85.1
52 Week Low 38.56
Average Volume 521,792
200-Day Moving Average 57.1891
50-Day Moving Average 53.6024
20-Day Moving Average 48.8895
10-Day Moving Average 46.491
Average True Range 2.4826
ADX 31.25
+DI 13.1722
-DI 26.5925
Chandelier Exit (Long, 3 ATRs ) 48.2622
Chandelier Exit (Short, 3 ATRs ) 50.4978
Upper Bollinger Band 55.1174
Lower Bollinger Band 42.6616
Percent B (%b) 0.17
BandWidth 25.477454
MACD Line -2.4279
MACD Signal Line -2.1173
MACD Histogram -0.3106
Fundamentals Value
Market Cap 1.38 Billion
Num Shares 30.9 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -16.62
Price-to-Sales 99.62
Price-to-Book 4.15
PEG Ratio 1.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.63
Resistance 3 (R3) 46.81 46.36 46.31
Resistance 2 (R2) 46.36 45.87 46.27 46.20
Resistance 1 (R1) 45.54 45.58 45.32 45.36 46.10
Pivot Point 45.09 45.09 44.98 45.00 45.09
Support 1 (S1) 44.27 44.60 44.05 44.09 43.34
Support 2 (S2) 43.82 44.31 43.73 43.24
Support 3 (S3) 43.00 43.82 43.13
Support 4 (S4) 42.82